The dose characteristics in the SIR-Spheres® Y-90 resin microspheres arm, were as follow:
| Average cumulative lung dose per patient (range), Gy | 2.6 (1.2-4.8) |
| Average activity delivered per session (range), GBq | 0.95 (0.63–1.22) |
| Average activity delivered per patient (range), GBq | 1.39 (0.99–1.85) |
The activity was calculated using the modified Body-Surface Area (BSA) method.
71,7% of the treatments were lobar treatments and the majority (62,5%) were unilobar.
Patients with multiple sessions could have ipsi-lateral or contra-lateral treatment. 31.5% of the treatments were second-treatment and 6% were third-treatment, either ipsi- or contra-lateral.
In the sorafenib arm, the treatment characteristics were as follows:
| Dose intensity, median (IQR), mg | 800 (585–800) |
| Cumulative time of intake, median (IQR), months | 2.8 (1.0–5.8) |
| Sorafenib dose reduction | 38% |
| Permanent discontinuation rate (PDR) | 61% |
| Including PDR prior to tumour progression | 37% |
Vilgrain V et al. Lancet Oncol 2017; 18: 1624–36.